Biotechnology - Rare diseases, Kalydeco

Filter

Current filters:

Rare diseasesKalydeco

Popular Filters

FDA advisory backs expanded use of Vertex’ CF drug

22-10-2014

There was good news for US biotech firm Vertex Pharmaceuticals yesterday, as a US Food and Drug Administration…

BiotechnologyKalydecoRare diseasesRegulationUSAVertex Pharmaceuticals

Vertex leaps on positive Ph III results with lumacaftor

Vertex leaps on positive Ph III results with lumacaftor

24-06-2014

US biotech firm Vertex Pharmaceuticals saw its share price rocket nearly 52% to $101.20 in extending…

BiotechnologyBusiness FinanceCystic fibrosisHealth Medical PharmaKalydecolumacaftorMedicinePhenolsRare diseasesRegulationResearchVertex Pharmaceuticals

FDA backs Kalydeco for eight additional mutations that cause cystic fibrosis

22-02-2014

The US Food and Drug Administration approved biotech firm Vertex Pharmaceuticals’ supplemental New…

BiotechnologyKalydecoNorth AmericaRare diseasesRegulationUSAVertex

Vertex outlines progress on cystic fibrosis drug development

17-10-2013

USA-based biotech firm Vertex Pharmaceuticals provided a comprehensive update on recent progress in its…

BiotechnologyKalydecolumacaftorRare diseasesResearchVertexVX-661

Vertex shoots up 60% on positive trial results for Kalydeco and VX-661

22-04-2013

US biotech firm Vertex Pharmaceuticals' (Nasdaq: VRTX) shares rocketed 60% to $84.87 Friday morning after…

BiotechnologyKalydecoRare diseasesResearchVertexVX-661

Health Canada approves Vertex' Kalydeco; and Sanofi Pasteur's Menactra

03-12-2012

Vertex Pharmaceuticals (Nasdaq: VRTX) says that Health Canada has approved Kalydeco (ivacaftor), the…

BiotechnologyKalydecoMenactraNorth AmericaPharmaceuticalRare diseasesRegulationSanofiSanofi PasteurVaccinesVertex

Back to top